Author’s response to reviews

Title: Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens

Authors:

Naohisa Yoshida (naohisa@koto.kpu-m.ac.jp)
Tetsuya Taguchi (ttaguchi@koto.kpu-m.ac.jp)
Masayoshi Nakanishi (mnakan@koto.kpu-m.ac.jp)
Ken Inoue (keninoue71@koto.kpu-m.ac.jp)
Tetsuya Okayama (t-oka@koto.kpu-m.ac.jp)
Takeshi Ishikawa (iskw-t@koto.kpu-m.ac.jp)
Eigo Otsuji (otsuji@koto.kpu-m.ac.jp)
Koichi Takayama (takayama@koto.kpu-m.ac.jp)
Haruo Kuroboshi (rangaku@koto.kpu-m.ac.jp)
Motohiro Kanazawa (motohiro@koto.kpu-m.ac.jp)
Yoshito Itoh (yitoh@koto.kpu-m.ac.jp)

Version: 3 Date: 05 Dec 2018

Author’s response to reviews:

PHAT-D-18-00204R2

Efficacy of the combination use of apreptitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens Naohisa Yoshida; Tetsuya Taguchi; Masayoshi Nakanishi; Ken Inoue; Tetsuya Okayama; Takeshi Ishikawa; Eigo Otsuji; Koichi Takayama; Haruo Kuroboshi; Motohiro Kanazawa; Yoshito Itoh
Dear Dr. Benjamin Ragen,

Editor of BMC Pharmacology and Toxicology

We are very glad to your consideration for the publication of our manuscript for BMC Pharmacology and Toxicology. We changed detail of draft according to peer review’s comments. I would like to receive good news from you.

Sincerely,

Naohisa Yoshida

Department of Molecular Gastroenterology and Hepatology,
Kyoto Prefectural University of Medicine
Graduate School of Medical Science

Editor Comments:

1. Please revise your Ethics approval and consent to participate section to include a statement regarding ethics approval for this study. We notice some of this information is already included in the Methods section (page 11), so please include again in the Ethics approval section.

Answer: Thank you for your comments. We changed it.

2. Please note that the Consent for publication statement refers to consent obtained to include any individual person’s data in any form (including individual details, images or videos). Therefore, please state "Not applicable" in this section as no personal information is provided in your manuscript. The statement regarding authors’ approval of the final manuscript should instead be included in the Authors’ contributions section of the Declarations.
Answer: Thank you for your comments. We changed it.

3. The individual contributions of authors to the manuscript should be specified in the Authors’ contributions section of the Declarations. Please note that all authors should be named by using their initials rather than full names, and also include a statement clearly indicating that all authors read and approved the final version of the manuscript.

Answer: Thank you for your comments. I included the sentence “All authors (N.Y., T.T, M.N., K.T., T.O., E.O., T.I., K.T., H.K., M.K., Y.I.) read and approved the final version of the manuscript.”.

4. Please remove the abbreviations file from the file inventory, as it is no longer needed at this stage of the editorial process. The list of abbreviations should remain in the main manuscript and please remove any abbreviations that are not used. For example, the abbreviation UMIN-CTR was not found elsewhere in the manuscript.

Answer: Thank you for your comments. I removed it and checked all abbreviations again.

5. At this stage, we ask that you submit a clean version of your manuscript and do not include track changes or highlighting.

Answer: Thank you for your comments. I downloaded the clean version.